Source: Neuro-Oncology. Unidade: FMRP
Subjects: MENINGIOMA, METILAÇÃO, DNA, RADIOTERAPIA, ESTUDOS DE VALIDAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NASSIRI, Farshad et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, v. 21, n. 7, p. 901-910, 2019Tradução . . Disponível em: https://doi.org/10.1093/neuonc/noz061. Acesso em: 21 ago. 2024.APA
Nassiri, F., Mamatjan, Y., Suppiah, S., Badhiwala, J. H., Mansouri, S., Karimi, S., et al. (2019). DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 21( 7), 901-910. doi:10.1093/neuonc/noz061NLM
Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Noushmehr H. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management [Internet]. Neuro-Oncology. 2019 ; 21( 7): 901-910.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1093/neuonc/noz061Vancouver
Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Noushmehr H. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management [Internet]. Neuro-Oncology. 2019 ; 21( 7): 901-910.[citado 2024 ago. 21 ] Available from: https://doi.org/10.1093/neuonc/noz061